Serenex to Present at Acumen Biofin Rodman &Amp; Renshaw 9th Annual Healthcare Conference
Serenex, Inc., a leader in the discovery and development of small molecule Heat Shock Protein 90 (Hsp90) inhibitors, announced today that Dr. Richard Kent, chief executive officer, is scheduled to present at the Rodman & Renshaw 9th Annual Healthcare Conference taking place in New York at The Palace Hotel.
On Monday, November 5 at 11:15 am EST, Dr. Kent will present an overview of the company including recent clinical data relating to SNX-5422, the Company’s oral, totally synthetic small molecule, phase 1 Hsp90 inhibitor. A replay of the presentation will be available under the “News” section of the Serenex website (www.serenex.com) approximately 12 hours after the presentation for a period of 90 days.
About Serenex
Serenex is an integrated drug discovery and development company and a leader in the discovery and development of small molecule Hsp90 inhibitors. Serenex has a novel small molecule inhibitor of Heat Shock Protein 90 (Hsp90), SNX-5422, which is in phase 1 clinical trials. SNX-5422 was developed from the Company’s Hsp90 Product Platform, a proprietary collection of several hundred potent small molecule Hsp90 inhibitors. Hsp90 is a central protein responsible for chaperoning a large number of oncogenic and other proteins and is believed to play a key role in cancer, inflammatory diseases, fungal infection resistance, viral diseases and neurodegenerative diseases such as Alzheimer’s. Serenex has ongoing pre-clinical programs in all of these areas. Additionally, Serenex is developing SNX-1012, a product for oral mucositis in solid tumor patients scheduled to complete phase 2 clinical trials in early 2008. Serenex’s pipeline is powered by a proprietary high throughput screening platform which enables the company to profile compounds, en masse, against thousands of important therapeutic and toxicity targets. Website: www.serenex.com.
CONTACT: Ian Howes CFO & Sr. V.P. Corporate Development Serenex, Inc. 919/281-6001 Email Contact Michelle Linn Linnden Communications 508/419-1555 Email Contact
SOURCE: Serenex